Breaking News

AbbVie Acquires Aliada for $1.4B

Acquisition adds ALIA-1758, a potential best-in-class disease-modifying therapy for Alzheimer's disease.

Author Image

By: Charlie Sternberg

Associate Editor

AbbVie has completed its previously announced acquisition of Aliada Therapeutics, a biotechnology company developing therapies using a novel blood-brain barrier (BBB)-crossing technology for central nervous system (CNS) diseases. The transaction was valued at $1.4 billion.   Aliada’s lead investigational asset utilizing its delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer’s disease.   “Alzh...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters